new_0222_0158|KYMR|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0158|KYMR|1|Kymera Therapeutics Inc Total Current Assets (Quarterly) (USD)|Kymera Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Kymera Therapeutics Inc Inventories (Quarterly) (USD)|Kymera Therapeutics Inc Net PP&E (Quarterly) (USD)|Kymera Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Kymera Therapeutics Inc Total Liabilities (Quarterly) (USD)|Kymera Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Kymera Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Kymera Therapeutics Inc Total Deposits (Quarterly) (USD)|Kymera Therapeutics Inc Book Value (Quarterly) (USD)|Kymera Therapeutics Inc Retained Earnings (Quarterly) (USD)|Kymera Therapeutics Inc Treasury Stock (Quarterly) (USD)|Kymera Therapeutics Inc EV to Revenues|Kymera Therapeutics Inc EV to Earnings|Kymera Therapeutics Inc EV to Free Cash Flow|Kymera Therapeutics Inc EV to Assets (Quarterly)|Kymera Therapeutics Inc PS Ratio|Kymera Therapeutics Inc PE Ratio|Kymera Therapeutics Inc Price to Book Value|Kymera Therapeutics Inc PEG Ratio|Kymera Therapeutics Inc Debt to Equity Ratio|Kymera Therapeutics Inc Dividend Yield|Kymera Therapeutics Inc Shareholder Yield (TTM)|Kymera Therapeutics Inc Percent of Shares Outstanding Short|Kymera Therapeutics Inc Total Receivables (Quarterly) (USD)|Kymera Therapeutics Inc Total Payables (Quarterly) (USD)|Kymera Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Kymera Therapeutics Inc Return on Invested Capital|Kymera Therapeutics Inc Quality Ratio Score|Kymera Therapeutics Inc Momentum Score|Kymera Therapeutics Inc Beta (1Y)|Kymera Therapeutics Inc Sustainable Growth Rate (TTM)|Kymera Therapeutics Inc Institutional Investor Ownership Percentage|Kymera Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Kymera Therapeutics Inc Total Employees (Annual)|Kymera Therapeutics Inc EPS Diluted (Quarterly) (USD)|Kymera Therapeutics Inc Shares Outstanding|Kymera Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Kymera Therapeutics Inc Ordinary Shares Number (Quarterly)|Kymera Therapeutics Inc Payout Ratio|Kymera Therapeutics Inc Quick Ratio (Quarterly)|Kymera Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Kymera Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Kymera Therapeutics Inc Effective Tax Rate (TTM)|Kymera Therapeutics Inc Return on Equity|Kymera Therapeutics Inc Net Income (TTM) (USD)|Kymera Therapeutics Inc Revenue (TTM) (USD)|Kymera Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Kymera Therapeutics Inc Revenue (Quarterly) (USD)|Kymera Therapeutics Inc Gross Profit (Quarterly) (USD)|Kymera Therapeutics Inc SG&A Expense (Quarterly) (USD)|Kymera Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Kymera Therapeutics Inc Net Income (Quarterly) (USD)|Kymera Therapeutics Inc Net Interest Income (Quarterly) (USD)|Kymera Therapeutics Inc Price (USD)|Kymera Therapeutics Inc Total Return Price (USD)|Kymera Therapeutics Inc Enterprise Value (USD)|Kymera Therapeutics Inc 30-Day Average Daily Volume|Kymera Therapeutics Inc 1 Year Price Returns (Daily)||
new_0222_0158|KYMR|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0158|KYMR|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
new_0222_0158|KYMR|5|106.5|106.5|0|106.5|0|106.5|106.5|106.5|0|106.5|106.5|0|1.44892473118|91.25|1.44839857651|91.25|1.44892473118|0|1.44892473118|0|91.2857142857|1.44892473118|91.25|15.2352941176|106.5|106.5|106.5|91.25|0|30.75|30.6|91.25|0|91.375|91.4|91.375|31.2857142857|0|106.5|91.4|91.2857142857|91.375|91.25|0|91.25|91.4|91.4|0|91.375|0|91.375|91.375|91.375|91.375|1.44892473118|1.44892473118|1.44892473118|1.44897959184|1.43333333333||
new_0222_0158|KYMR|6|6|6|0|6|0|6|6|6|0|6|6|0|372|4|281|4|372|0|372|0|7|372|4|34|6|6|6|4|0|4|5|4|0|8|5|8|14|0|6|5|7|8|4|0|4|5|5|0|8|0|8|8|8|8|372|372|372|343|120||
new_0222_0158|KYMR|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0158|KYMR|201909||||||||||||||||||||||||||||||||||30.1951||-0.3782||||||-0.3782|||||||0.95||1.501|-11.42|-11.42|0.441|||||||
new_0222_0158|KYMR|201912|92.845|91.957||22.083||191.108|34.57|156.538||-74.406|-76.456||||||||||0||||0|3.276|0|||||||30.1951||-0.3813|||41.7241||2.66|-0.3813|||||||1.833||2.53|-11.513|-11.513|0.27|||||||
new_0222_0158|KYMR|202003||||||||||||||||||||||||||||||||||30.1951||-0.6618||||||-0.362|||||||3.428||2.559|-10.932|-10.932|0.315|||||||
new_0222_0158|KYMR|202006|158.301|155.965||20.285||77.066|42.68|34.386||104.043|-108.094||133.122||||111.0819||13.6529||0|0||0.4413||3.982|0.003|||||||41.7241|55|-0.3353|44.5295||41.7241|0|3.6543|-0.3353||||-47.854|9.499||3.288||3.661|-13.989|-13.989|0.203|31.9|31.9|1264.526||||
new_0222_0158|KYMR|202009|297.364|293.841||20.943||212.676|107.286|105.39||294.685|-116.08||49.4872|-25.7151||2.2514|42.9707||4.8734||0|0|0|1.3405|0.577|3.979|0.004|-41.0888||||-41.0888|60.7036|20.6774|64|-0.39|44.4477||44.4477|0|2.7442|-0.39|-196.275||-41.0888|-44.42|23.082||14.533||6.838|-7.986|-7.986|0.097|32.31|32.31|1142.2642|115242.6667||35.99|46.64
new_0222_0158|KYMR|202012|302.339|296.202||20.686||203.287|110.617|92.67||283.888|-128.765||72.3304|-53.994|31.1473|5.053|62.4294||9.7147||0|0|0|2.3605|1.433|4.368|0.004|-29.9844||||-29.9844||44.4822|75|-0.29|44.4822||44.4822|0|2.6907|-0.29|-0.398||-29.9844|-45.592|34.034||12.785||5.175|-12.685|-12.685|0.097|62|62|2461.6944|219880.3||61.95|47.98
new_0222_0158|KYMR|202103|340.791|333.537||20.502||189.305|110.137|79.168||275.247|-141.84||28.6054|-29.5481|20.2949|3.0362|29.8561||6.3362||0|0|0|4.8232|1.734|8.348|0.004|-19.934||||-27.016||44.6496|92|-0.29|44.8794||44.8794|0|3.0441|-0.29|||-27.016|-47.735|49.308||18.702||5.909|-13.075|-13.075|0.094|38.86|38.86|1410.4765|507145.2||45.55|48.09
new_0222_0158|KYMR|202106|364.806|359.107||21.766||176.282|108.685|67.597||258.104|-166.5||28.4988|-31.4914|34.2965|4.2342|29.1018||8.5175||0|0|-8.9462|5.1997|0.904|8.177|0.005|-24.0163|||1.4147|-24.0163||45.0942|112|-0.55|45.3277||45.3277|0|3.3124|-0.55|||-24.0163|-58.406|64.539||18.519||8.029|-24.66|-24.66|0.07|48.5|48.5|1839.2864|473162.5333|94.7962|60.18|62.14
new_0222_0158|KYMR|202109|543.731|536.386||21.724||159.318|94.493|64.825||483.135|-195.082||35.1771|-31.3211|-21.8599|3.8515|38.6093||6.2318||0|0|-8.0886|3.2102|1.573|5.033|0.005|-24.7646||8|1.6171|-24.7646||50.7148|136|-0.56|51.2566||51.2566|0|5.6931|-0.56|-243.135||-24.7646|-79.002|70.342||20.336||10.667|-28.582|-28.582|0.055|58.74|58.74|2474.4267|380982.5333|81.8013|58.88|55.52
new_0222_0158|KYMR|202112|||||||||||||38.7561||-24.0839||41.7314||6.7529|||0||3.8527||||||6|0.7801||||||||||||||||||||||||63.49|63.49|2726.181|323057.9333|2.4032|42|42.04